Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Radiotherapy with rituximab may be better than radiotherapy alone in first-line treatment of early-stage follicular lymphoma: is it time to change the standard strategy

A. Janikova, Z. Bortlicek, V. Campr, N. Kopalova, K. Benesova, D. Belada, V. Prochazka, R. Pytlik, S. Vokurka, J. Pirnos, J. Duras, H. Mocikova, J. Mayer, M. Trneny,

. 2015 ; 56 (8) : 2350-2356. [pub] 20150121

Language English Country England, Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc16021030

Grant support
NT12193 MZ0 CEP Register

Early-stage follicular lymphoma (FL) has traditionally been treated with involved-field radiotherapy (RT). Rituximab (R) is a low-toxic, efficient systemic therapy for FL, but there are no data about its clinical impact in early FL. We retrospectively analyzed 93 patients with stage I-II indolent FL treated with RT (n=65) or RT+R (n=14) or R alone (n=14). Median follow-up was 5.0 years for patients with RT, 2.8 years for the RT+R subgroup and 2.5 years for patients treated with R. The complete response rate was 92%, 100% and 86% (not significant) and the median PFS was 3.3 years, not reached and 4.9 years (p=0.035) for the RT, RT+R and R arms, with no impact on overall survival. R combined with RT seems to give better results in terms of global FL control, but longer follow-up and prospective comparison are needed to verify these results.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16021030
003      
CZ-PrNML
005      
20250424111643.0
007      
ta
008      
160722s2015 enk f 000 0|eng||
009      
AR
024    7_
$a 10.3109/10428194.2014.990010 $2 doi
024    7_
$a 10.3109/10428194.2014.990010 $2 doi
035    __
$a (PubMed)25426666
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Janíková, Andrea $u Department of Internal Medicine - Hematology and Oncology , Masaryk University and University Hospital Brno , Brno , Czech Republic. $7 xx0103433
245    10
$a Radiotherapy with rituximab may be better than radiotherapy alone in first-line treatment of early-stage follicular lymphoma: is it time to change the standard strategy / $c A. Janikova, Z. Bortlicek, V. Campr, N. Kopalova, K. Benesova, D. Belada, V. Prochazka, R. Pytlik, S. Vokurka, J. Pirnos, J. Duras, H. Mocikova, J. Mayer, M. Trneny,
520    9_
$a Early-stage follicular lymphoma (FL) has traditionally been treated with involved-field radiotherapy (RT). Rituximab (R) is a low-toxic, efficient systemic therapy for FL, but there are no data about its clinical impact in early FL. We retrospectively analyzed 93 patients with stage I-II indolent FL treated with RT (n=65) or RT+R (n=14) or R alone (n=14). Median follow-up was 5.0 years for patients with RT, 2.8 years for the RT+R subgroup and 2.5 years for patients treated with R. The complete response rate was 92%, 100% and 86% (not significant) and the median PFS was 3.3 years, not reached and 4.9 years (p=0.035) for the RT, RT+R and R arms, with no impact on overall survival. R combined with RT seems to give better results in terms of global FL control, but longer follow-up and prospective comparison are needed to verify these results.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a protinádorové látky $x terapeutické užití $7 D000970
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a chemoradioterapie $7 D059248
650    _2
$a kombinovaná terapie $7 D003131
650    _2
$a databáze faktografické $7 D016208
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a folikulární lymfom $x epidemiologie $x patologie $x terapie $7 D008224
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mortalita $7 D009026
650    _2
$a staging nádorů $7 D009367
650    12
$a radioterapie $x metody $7 D011878
650    _2
$a rituximab $x terapeutické užití $7 D000069283
650    _2
$a standardní péče $7 D059039
650    _2
$a výsledek terapie $7 D016896
651    _2
$a Česká republika $x epidemiologie $7 D018153
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Bortlíček, Zbyněk $u Institute of Biostatistics and Analyses, Faculty of Medicine and Faculty of Science, Masaryk University , Brno , Czech Republic. $7 xx0194424
700    1_
$a Campr, Vít, $u Department of Pathology and Molecular Medicine , 2nd Faculty of Medicine, Charles University and Faculty Hospital in Motol , Prague , Czech Republic. $d 1960- $7 jo2002148777
700    1_
$a Kopálová, Nataša $u Department of Internal Medicine - Hematology and Oncology , Masaryk University and University Hospital Brno , Brno , Czech Republic. $7 xx0331481
700    1_
$a Benešová, Kateřina $u 1st Department of Medicine , Charles University General Hospital , Prague , Czech Republic. $7 xx0039312
700    1_
$a Belada, David, $u Department of Clinical Hematology , University Hospital Hradec Kralove , Hradec Kralove , Czech Republic. $d 1972- $7 mzk2006322730
700    1_
$a Procházka, Vít $u Department of Hematology , University Hospital Olomouc , Olomouc , Czech Republic. $7 xx0143822
700    1_
$a Pytlík, Robert, $u 1st Department of Medicine , Charles University General Hospital , Prague , Czech Republic. $d 1967- $7 xx0061345
700    1_
$a Vokurka, Samuel $u Department of Hematooncology , Charles University and University Hospital Pilsen , Pilsen , Czech Republic. $7 mzk2005309233
700    1_
$a Pirnos, Jan $u Department of Oncology , Hospital Ceske Budejovice , Ceske Budejovice , Czech Republic. $7 xx0081863
700    1_
$a Duras, Juraj $u Department of Clinical Hematology , Teaching Hospital Ostrava , Ostrava , Czech Republic.
700    1_
$a Móciková, Heidi, $u Department of Hematology , University Hospital Kralovske Vinohrady , Prague , Czech Republic. $d 1964- $7 mzk2009517509
700    1_
$a Mayer, Jiří, $u Department of Internal Medicine - Hematology and Oncology , Masaryk University and University Hospital Brno , Brno , Czech Republic. $d 1960- $7 nlk20000083651
700    1_
$a Trněný, Marek, $u 1st Department of Medicine , Charles University General Hospital , Prague , Czech Republic. $d 1960- $7 nlk20000083659
773    0_
$w MED00003140 $t Leukemia & lymphoma $x 1029-2403 $g Roč. 56, č. 8 (2015), s. 2350-2356
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25426666 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160722 $b ABA008
991    __
$a 20250424111642 $b ABA008
999    __
$a ok $b bmc $g 1155700 $s 945558
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 56 $c 8 $d 2350-2356 $e 20150121 $i 1029-2403 $m Leukemia & lymphoma $n Leuk Lymphoma $x MED00003140
GRA    __
$a NT12193 $p MZ0
LZP    __
$a Pubmed-20160722

Find record

Citation metrics

Archiving options